234 related articles for article (PubMed ID: 11447309)
21. Effects of combined angiotensin II and endothelin receptor blockade with developing heart failure: effects on left ventricular performance.
New RB; Sampson AC; King MK; Hendrick JW; Clair MJ; McElmurray JH; Mandel J; Mukherjee R; de Gasparo M; Spinale FG
Circulation; 2000 Sep; 102(12):1447-53. PubMed ID: 10993866
[TBL] [Abstract][Full Text] [Related]
22. Cardioprotection by long-term ET(A) receptor blockade and ACE inhibition in rats with congestive heart failure: mono- versus combination therapy.
Fraccarollo D; Bauersachs J; Kellner M; Galuppo P; Ertl G
Cardiovasc Res; 2002 Apr; 54(1):85-94. PubMed ID: 12062365
[TBL] [Abstract][Full Text] [Related]
23. Endothelin antagonism in experimental ischemic heart failure: hemodynamic, structural and neurohumoral effects.
Mulder P; Richard V; Thuillez C
Heart Fail Rev; 2001 Dec; 6(4):295-300. PubMed ID: 11447304
[TBL] [Abstract][Full Text] [Related]
24. Endothelin A receptor antagonism in experimental congestive heart failure results in augmentation of the renin-angiotensin system and sustained sodium retention.
Schirger JA; Chen HH; Jougasaki M; Lisy O; Boerrigter G; Cataliotti A; Burnett JC
Circulation; 2004 Jan; 109(2):249-54. PubMed ID: 14691038
[TBL] [Abstract][Full Text] [Related]
25. Endothelin and endothelin receptor antagonism in heart failure.
Sütsch G; Kiowski W
J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S69-73. PubMed ID: 10976786
[TBL] [Abstract][Full Text] [Related]
26. Haemodynamic influence and endothelin-1 plasma concentrations by selective or non-selective endothelin receptor antagonists in the pig in vivo.
Holm P; Franco-Cereceda A
Acta Physiol Scand; 1999 Feb; 165(2):163-8. PubMed ID: 10090327
[TBL] [Abstract][Full Text] [Related]
27. Bosentan and the endothelin system in congestive heart failure.
Ellahham SH; Charlon V; Abassi Z; Calis KA; Choucair WK
Clin Cardiol; 2000 Nov; 23(11):803-7. PubMed ID: 11097125
[TBL] [Abstract][Full Text] [Related]
28. Role of endothelin-1 in myocardial failure.
Sam F; Colucci WS
Proc Assoc Am Physicians; 1999; 111(5):417-22. PubMed ID: 10519162
[TBL] [Abstract][Full Text] [Related]
29. Chronic endothelin blockade in dogs with pacing-induced heart failure: possible modulation of sympathoexcitation.
McConnell PI; Olson CE; Patel KP; Blank DU; Olivari MT; Gallagher KP; Quenby-Brown E; Zucker IH
J Card Fail; 2000 Mar; 6(1):56-65. PubMed ID: 10746820
[TBL] [Abstract][Full Text] [Related]
30. Endothelin in congestive heart failure.
Love MP; McMurray JJ
Basic Res Cardiol; 1996; 91 Suppl 1():21-9. PubMed ID: 8896740
[TBL] [Abstract][Full Text] [Related]
31. New developments in heart failure: role of endothelin and the use of endothelin receptor antagonists.
Suresh DP; Lamba S; Abraham WT
J Card Fail; 2000 Dec; 6(4):359-68. PubMed ID: 11145761
[TBL] [Abstract][Full Text] [Related]
32. Altered inotropic response of endothelin-1 in cardiomyocytes from rats with isoproterenol-induced cardiomyopathy.
Suzuki M; Ohte N; Wang ZM; Williams DL; Little WC; Cheng CP
Cardiovasc Res; 1998 Sep; 39(3):589-99. PubMed ID: 9861301
[TBL] [Abstract][Full Text] [Related]
33. Long-term survival and hemodynamics after endothelin-a receptor antagonism and angiotensin-converting enzyme inhibition in rats with chronic heart failure: monotherapy versus combination therapy.
Mulder P; Boujedaini H; Richard V; Henry JP; Renet S; Münter K; Thuillez C
Circulation; 2002 Aug; 106(9):1159-64. PubMed ID: 12196345
[TBL] [Abstract][Full Text] [Related]
34. The role of endothelins and their receptors in heart failure.
Giannessi D; Del Ry S; Vitale RL
Pharmacol Res; 2001 Feb; 43(2):111-26. PubMed ID: 11243712
[TBL] [Abstract][Full Text] [Related]
35. Pathophysiological roles of endogenous endothelin-1 in dogs with chronic heart failure produced by rapid right ventricular pacing.
Tadano K; Suzuki J; Hanada K; Nakao M; Nakao R; Uehara S; Ohta H; Miyauchi T; Nishikibe M
J Pharmacol Exp Ther; 2001 Aug; 298(2):729-36. PubMed ID: 11454937
[TBL] [Abstract][Full Text] [Related]
36. Endothelin mediates the altered renal hemodynamics associated with experimental congestive heart failure.
Qiu C; Ding SS; Hess P; Clozel JP; Clozel M
J Cardiovasc Pharmacol; 2001 Aug; 38(2):317-24. PubMed ID: 11483881
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
Spieker LE; Noll G; Lüscher TF
Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
[TBL] [Abstract][Full Text] [Related]
38. Endothelin stimulates an endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, in experimental heart failure.
Ohnishi M; Wada A; Tsutamoto T; Fujii M; Matsumoto T; Yamamoto T; Takayama T; Wang X; Kinoshita M
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():241S-244S. PubMed ID: 12193095
[TBL] [Abstract][Full Text] [Related]
39. Enhanced endothelin-1-induced contractions in mesenteric arteries from rats with congestive heart failure: role of ET(B) receptors.
Bergdahl A; Valdemarsson S; Adner M; Sun XY; Hedner T; Edvinsson L
Eur J Heart Fail; 2001 Jun; 3(3):293-9. PubMed ID: 11377999
[TBL] [Abstract][Full Text] [Related]
40. Sympathetic activation and the role of beta-blockers in chronic heart failure.
Krum H
Aust N Z J Med; 1999 Jun; 29(3):418-27. PubMed ID: 10868514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
